1.
|
Phase: Phase IV, Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: GPOH-NB2004, EU-20661, NCT00410631
|
|
2.
|
Phase: Phase IV
Type: Supportive care, Treatment
Status: Active
Age: 15 to 70
Sponsor: Other
Protocol IDs: OLSG-0401, NCT00162955
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL03, NCT00199004
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL05, NCT00199082
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 75
Sponsor: Other
Protocol IDs: CGC05MK1002, NCT00188149
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: SHEBA-06-4013-IK-CTIL, NCT00339118
|
|
8.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 45
Sponsor: Other
Protocol IDs: 0501-37, NCT00352872
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2006-003750-23, LINFOTARGAM, NCT00466258
|
|
11.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL04, NCT00199017
|
|
12.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: YUNZHI-BC, NCT00647075
|
|
13.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1. NHL, non, NCT00969462
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
|
|
15.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 59
Sponsor: Other
Protocol IDs: N06IAA, NCT00448266
|
|
16.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 12 to 80
Sponsor: Other
Protocol IDs: A-39/29.1.2007, ICMR No-5/8/7/26/99-ECD-I, NCT00522405
|
|
17.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: IFCT-0802, 2009-010187-42, NCT00930891
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: NCI
Protocol IDs: SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 18
Sponsor: Other
Protocol IDs: EORTC-58951, NCT00003728
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 22
Sponsor: Other
Protocol IDs: FRE-IGR-ALCL99, EU-20031, NHL2000/06, NCT00006455
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, NCT00020566, AEWS0331
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: IBCSG-22-00, EU-20119, NCT00022516, EUDRACT-2005-005666-36
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: MDA-ID-00156, NCI-3410, 3410, NCT00024167
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: EORTC-30994, ACOSOG-EORTC-30994, CAN-NCIC-EORTC-30994, FNCLCC-GETUG-EORTC-30994, NORDIC-EORTC-30994, UKCCCR-EORTC-30994, NCRI-BLADDER-EORTC-30994, NCT00028756
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-40101, NCT00041119
|
